



(Please scan this QR Code to view the RHP and Abridged Prospectus)



ABRIDGED PROSPECTUS
100% Book Built Issue
Dated: August 08, 2026
Please read Section 26 and 32 of the
Companies Act, 2013

CREDENT CONNECT N CARE LIMITED
(Formerly known as Credent Cold Chain Logistics
Private Limited)

CIN: U63000DL2015PLC281994

Registered Office	Corporate Office	Contact Person	Email and Telephone	Website
B-3, Second Floor, Nimri Commercial Complex, Ashok Vihar, Phase-4, New Delhi – 110 052, Delhi, India.	-	Arpita Abhilasha Company Secretary & Compliance Officer	Email: cs@c3logistics.co.in Telephone: +91-9971777199	https://c3logistics.co.in/

Promoter of the Company
Ashok Kumar Sharma, Karan Sharma, Tarun Sharma, Dimple Sharma and Tanveen

DETAILS OF THE ISSUE				
Type	Fresh Issue Size (in ₹ lakhs)	OFS Size (by no. of Shares or by amount in ₹)	Total Issue Size (in ₹ lakhs)	Eligibility
Fresh Issue	up to 49,68,000 Equity Shares aggregating up to ₹ [●] lakhs	Nil	[●]	This Issue is being made in terms of regulation 229(2) and 253(1) of chapter IX of the SEBI (ICDR) Regulations, 2018 as amended.
DETAILS OF OFFER FOR SALE, SELLING SHAREHOLDERS AND THEIR AVERAGE COST OF ACQUISITION- NOT APPLICABLE AS THE ENTIRE ISSUE CONSTITUTES FRESH ISSUE OF EQUITY SHARES				
RISK IN RELATION TO THE FIRST ISSUE				
This being the first issue of the issuer, there has been no formal market for the securities of the issuer. The face value of the Equity Shares is ₹10. The Floor Price, Cap Price and Issue Price determined by our Company, in consultation with the Book Running Lead Manager, on the basis of the assessment of market demand for the Equity Shares by way of the Book Building Process, as stated under “Basis for Issue Price” on page 97 should not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.				
GENERAL RISKS				
Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the Red Herring Prospectus. Specific attention of the investors is invited to the section “Risk Factors” beginning on page 21 of this Red Herring Prospectus.				
ISSUER ABSOLUTE RESPONSIBILITY				
Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Red Herring Prospectus contains all information with regard to our Company and the Issue, which is material in the context of the Issue, that the information contained in this Red Herring Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Red Herring Prospectus as a whole or any of such information or the expression of any such opinions or intentions, misleading in any material respect.				
LISTING				
The Equity Shares Issued through Red Herring Prospectus are proposed to be listed on the SME Platform of NSE (“NSE Emerge”). In terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018 as amended from time to time. For the purpose of this Issue, the Designated Stock Exchange will be the National Stock Exchange of India Limited (“NSE”).				
BOOK RUNNING LEAD MANAGER TO THE ISSUE				
Name and Logo		Contact Person	Email & Telephone	
 Hem Securities Hem Securities Limited		Neelkanth Agarwal	Email: ib@hemsecurities.com ; Tel. No.: +91-22- 49060000	
REGISTRAR TO THE ISSUE				
Name and Logo		Contact Person	Email & Telephone	
 KFINTECH KFin Technologies Limited		M Murali Krishna	Email: credentconnect.ipo@kfintech.com Tel No: +91 40 6716 2222	
BID/ISSUE PERIOD				
ANCHOR PORTION ISSUE OPENS/ CLOSES ON*: WEDNESDAY, AUGUST 12, 2026		BID/ ISSUE OPENS ON: THURSDAY, AUGUST 13, 2026		BID/ ISSUE CLOSES ON**: MONDAY, AUGUST 17, 2026***

*Our Company, in consultation with the BRLM, may consider participation by Anchor Investors, in accordance with the SEBI (ICDR) Regulations. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/Issue Opening Date.

**Our Company, in consultation with the BRLM, may decide to close the Bid/Issue Period for QIBs one Working Day prior to the Bid/Issue Closing Date, in accordance with the SEBI (ICDR) Regulations.

***The UPI mandate end time and date shall be at 5:00 p.m. on Bid/Issue Closing Day.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Please scan this QR code to view the Red Herring Prospectus and the Abridged Prospectus



The following is a general summary of certain disclosures in the Red Herring Prospectus and the terms of the Offer and is not exhaustive, nor does it purport to contain a summary of all the disclosures in the Red Herring Prospectus or all details relevant to prospective investors. This summary should be read in conjunction with, and is qualified in its entirety by the more detailed information appearing elsewhere in the Red Herring Prospectus, which is available at the websites of National Stock Exchange of India Limited at www.nseindia.com, the Company at <https://c3logistics.co.in/> and the BRLM at www.hemsecurities.com. References below to page numbers are to page numbers of the Red Herring Prospectus dated August 08, 2026. Unless otherwise specified all capitalized terms used herein and not specifically defined bear the same meaning as ascribed to them in the Red Herring Prospectus.

SUMMARY OF THE PRIMARY BUSINESS

Company Overview: Our company is a healthcare services provider engaged in delivering integrated logistics, workforce solutions, and technology-enabled support to healthcare institutions across India. We provide comprehensive operational and logistics services to diagnostic laboratories, In Vitro Diagnostics (IVD) companies, pharmaceutical companies, clinics, and other healthcare enterprises through end-to-end solutions.

Products/ Services Offerings: Our Services includes the followings:

1. Healthcare Logistics;
2. Operations & Supply Chain Management;
3. Diagnostic & Paramedical Services
4. Corporate Wellness
5. C3 Post including IT Services, Marketing Services and Professional Services.

Revenue Bifurcation of the Company:

(Amount in ₹ Lakhs)

Particular	Consolidated 2025-26		Standalone FY 2024-25		Standalone FY 2023-24	
	Amount	% of total Revenue	Amount	% of total revenue	Amount	% of total revenue
Revenue from Sale of services						
Logistics Services	5,410.66	25.26	5,042.15	64.69	2,943.82	38.87
Operations & Supply Chain Management	5,338.30	24.93	1,014.42	13.01	2,541.14	33.55
Health Care Services	9,218.18	43.04	949.20	12.18	1,480.87	19.55
Marketing Services	589.76	2.75	510.17	6.55	414.91	5.48
IT Services	600.95	2.81	200.00	2.57	190.00	2.51
Corporate & Wellness (Camp)	18.09	0.08	14.06	0.18	2.58	0.03
Professional Fees	35.25	0.16	64.27	0.82	-	-
Sale of IT Software Products	205.00	0.96	-	-	-	-
Total	21,416.18	100.00	7,794.26	100.00	7,573.32	100.00

*As certified by R K Jagetiya & Co., Peer review Statutory Auditor, through its certificate dated July 31, 2026.

Geographies Served: We have operations across multiple states in India, which form our primary area of operation. Our presence spans Maharashtra, Uttar Pradesh, Delhi, Karnataka, Haryana, Telangana, and Rajasthan, contributing to revenue across regions. For the year ended March 31, 2026, Maharashtra contributed 29.40% of our total revenue, followed by Uttar Pradesh at 26.83%, Delhi at 10.93%, Karnataka at 10.55%, Haryana at 9.67%, Telangana at 3.19%, and Rajasthan at 3.23%. This geographic coverage allows us to deliver healthcare services and logistics solutions across a wide range of locations in the domestic market.

Contribution of Top 10 Customers and Top 10 Suppliers

The table below sets out the percentage contribution of the Company's top 10 Customers and top 10 suppliers to its total revenue from operations and total purchases, respectively, for the years indicated.

Particular	March 31, 2026	March 31, 2025	March 31, 2024
Top 10 Customer	81.76%	83.31%	87.92%
Top 10 Supplier	46.97%	37.06%	22.70%

KEY MANUFACTURING OR OTHER FACILITIES

Registered Office	B-3, Second Floor, Nimri Commercial Complex, Ashok Vihar, Phase 4, New Delhi, 110052, Delhi
Admin Office	3 rd floor, B-3, Nimri Commercial Complex, Ashok Vihar, Phase-4, Delhi-110052
Warehouses	B-4, Nimri Commercial Centre, Ashok Vihar, Phase-IV, Delhi, 110052
Branch Office & Warehouse	A-416, Lower Ground, Gali No, 10 Road No. 4, MahipalPur New Delhi-110037.
Branch Offices	Office No. B 227, 2 nd floor, Sohrab Hall CHS, Tadiwala Rd, Sangamwadi, Ghorapadi, Haveli, Pune, Maharashtra, 411001
	1 st Floor, Building No C-21/4D, Maldahia Varansi, UP-221002
	Office No. 2D6-A, Gundecha Onclave, Khairani Road Sakinaka, Andheri East, Mumbai, 400072
	Flat no- G 63, MHV Pinnacle, Door No. 27, Ground floor, Govindu Street, Off G.N. Chetty Street, T Nagar, Chennai – 600 017

BUSINESS STRENGTHS AND STRATEGIES

STRENGTH

1. Comprehensive Healthcare Ecosystem and Logistics Platform
2. Well established relationships with clients
3. Leveraging the experience of our Promoters and Directors
4. Widespread reach in domestic markets

STRATEGIES

1. Continue to invest in technological capabilities
2. Deepen Client Engagement and Expand Services
3. Attract, develop and retain skilled employees
4. Enhancing Operating Effectiveness and Efficiency

For further details, please refer to the chapter titled **“Our Business”** beginning on page 119 of the Red Herring Prospectus.

SUMMARY OF THE INDUSTRY

Logistics plays a critical role in ensuring reliability, speed, and regulatory compliance across the medical diagnostics value chain. The medical diagnostics industry relies on a highly coordinated logistics ecosystem designed to move biological samples, test kits, consumables, and medical documentation with accuracy, speed, and regulatory compliance. Unlike general logistics, diagnostic logistics must operate within strict time temperature windows, follow biosafety norms, and maintain sample integrity to ensure reliable test outcomes. As India's diagnostics sector expands through centralized processing laboratories, hub- and- spoke networks, and home- collection models, specialized logistics partners have emerged offering end- to- end solutions integrated with digital tracking, route optimization, and quality assurance systems. These logistics services are critical for supporting faster turnaround times (TAT), minimizing pre-analytical errors, and enabling nationwide coverage, including Tier II/III cities. (Source: D&B Industry report).

For further details please refer to the chapter titled **“Industry Overview”** beginning on page 107 of the Red Herring Prospectus.

PROMOTERS OF THE ISSUER COMPANY			
Sr. No.	Name	Individual/ Corporate	Experience & Educational Qualification
1.	Ashok Kumar Sharma	Individual	Ashok Kumar Sharma aged 67 years is Promoter and Non - Executive Director of our Company. He has been on the board as Non-Executive Director since September 30, 2025. He has completed his Higher Secondary Education in 1978 from Central Board of Secondary Education, New Delhi and has overall work experience of more than 14 years. His work experience primarily in the domain of administration, co-ordination for day to day functions, ensuring process and timeline, documentation and communication to support smooth office functioning.
2.	Karan Sharma	Individual	Karan Sharma aged 36 years is the Promoter, Whole Time Director & Chief Financial Officer of our Company. He has been associated with our company from 2018. He has an overall experience of around 09 years in the healthcare supply chain optimization, Technology integration & Tracking, vendor & Stakeholder Management. He has completed his Master of Business Administration from Sikkim Manipal University in the year 2021. He is currently involved in the accounts and finance and administrative activities of the company.
3.	Tarun Sharma	Individual	Tarun Sharma aged 39 years is the Chairman & Managing Director and Promoter of our Company. He has been on the Board since October 01, 2025. He has completed his Bachelors of Commerce (Honours) in 2024 from Kalinga University, Raipur and has overall work experience of around 12 years. His work experience primarily in the domain of healthcare logistics. cold-chain industry, diagnostic logistics, cold chain management, healthcare technology solutions, and paramedical service delivery.
4.	Dimple Sharma	Individual	Dimple Sharma aged 40 years is Promoter and Non-Executive Director of Our company. She has been on the board as Non-executive director since September 30, 2022. She has completed her Senior Secondary education in 2003. She has overall experience of 14 years primarily in the domain of Human resources and administration.
5.	Tanveen	Individual	Tanveen aged 46 years, is Promoter of the Company. She has been completed MBA in 2014 from Sikkim Manipal University. She has over 14 years of experience in Administration, Budgeting, facility management etc.

For details in respect of our Promoters, please refer to the chapter titled “Our Promoters and Promoter Group” beginning on page 167 of the Red Herring Prospectus.

OBJECTS OF THE ISSUE

The Issue includes a fresh Issue of up to 49,68,000 Equity shares of face value of ₹ 10 each aggregating [●] lakhs of our Company at an Issue Price of ₹ [●] per equity share are stated as follows:

(Amount in ₹ Lakhs)

S. No.	Particulars	Amount
1.	Investment in our wholly owned subsidiary, Credent Healthcare Private Limited to meet its working capital requirement	2,680.00
2.	Investment in our wholly owned subsidiary, Credent Healthcare Private Limited to finance its capital expenditure requirements for machinery	300.00
3.	To meet Working Capital Requirements	3,700.00
4.	Repayment and/or repayment, in full or part, of borrowing availed by our Company	600.00
5.	General corporate purposes*	[●]
	Total*	[●]

* To be finalized upon determination of the Issue Price and updated in the prospectus prior to filing with the RoC. The amount utilized for general corporate purpose shall not exceed 15% of the Gross Proceeds or ₹ 10 crores whichever is lower.

For further details, please refer to the chapter titled “Objects of the Issue” on page 87 of the of the Red Herring Prospectus.

PRE AND POST ISSUE SHAREHOLDING OF PROMOTER(S), MEMBERS OF THE PROMOTER GROUP, TOP 10 SHAREHOLDERS AND OTHER PUBLIC SHAREHOLDERS

Sr. No.	Pre-Issue shareholding as at the date of Advertisement			Post-Issue shareholding as at Allotment [#]	
	Shareholders	Number of Equity Shares	Shareholding (in %)	At Floor Price and at Cap Price	
				Number of Equity Shares	Shareholding (in %)
Promoters					
1.	Ashok Kumar Sharma	36,58,950	27.60	36,58,950	20.08
2.	Karan Sharma	22,47,825	16.96	22,47,825	12.34
3.	Tarun Sharma	20,23,550	15.27	20,23,550	11.10
4.	Dimple Sharma	1,32,550	1.00	1,32,550	0.73
5.	Tanveen	35,38,125	26.69	35,38,125	19.42
	Sub Total (A)	1,16,01,000	87.52	1,16,01,000	63.66
Promoter Group					
1.	Ashok Kumar Sharma HUF	5100	0.04	5100	0.03
2.	Karan Sharma HUF	5100	0.04	5100	0.03
3.	Tarun Sharma HUF	5100	0.04	5100	0.03
4.	Sub Total (B)	15,300	0.12	15,300	0.09
Public					
1.	Amit Gupta	7,65,000	5.77	7,65,000	4.20
2.	Ashish Kacholia	2,67,600	2.02	2,67,600	1.47
3.	Abakkus Venture Opportunities Fund	1,60,800	1.21	1,60,800	0.88
4.	Convivial Advisors LLP	1,42,200	1.07	1,42,200	0.78
5.	Ankaa Rise	27,000	0.20	27,000	0.15
6.	Chintan Natwar Kothari	27,000	0.20	27,000	0.15
7.	Pooja Jain	27,000	0.20	27,000	0.15
8.	SB Opportunities Fund II	27,000	0.20	27,000	0.15
9.	Tattvam AIF Trust - Aanjay Ageless AIF Fund	27,000	0.20	27,000	0.15
10.	Tiger Strategies Fund -I	27,000	0.20	27,000	0.15
11.	Sushma Chandna	26400	0.20	26400	0.14
12.	Anish Natwar Kothari	13,200	0.10	13,200	0.07
13.	Bhupendra Kumar Dak	13,200	0.10	13,200	0.07
14.	Divisha Gupta	13,200	0.10	13,200	0.07
15.	Pravah Ranka	13,200	0.10	13,200	0.07
16.	Sanjay Kumar Agarwal	13,200	0.10	13,200	0.07
17.	Umesh Kumar Jain	13,200	0.10	13,200	0.07
18.	Varun Kumar	13,200	0.10	13,200	0.07
19.	Rakesh Tarway	10,200	0.08	10,200	0.06
20.	Shivang Bhavesh Joshi	7,800	0.06	7,800	0.04
21.	Anita Devendrasing Rajput	4,200	0.03	4,200	0.02
	Sub Total (C)	16,38,600	12.36	16,38,600	8.99
	Grand Total (A+B+C)	1,32,54,900	100.00	1,32,54,900	72.74%

[#] Assuming full subscription of the offer. The post-offer shareholding details as at the Allotment will be based on the actual subscription, the Offer Price and updated Prospectus, subject to finalisation of the Basis of Allotment. Further, assuming that there is no transfer of shares by the shareholders between the date of Price Band advertisement and Allotment, and if any such transfer occurs prior to the date of the Prospectus, it will be updated in the shareholding pattern in the Prospectus.

SUMMARY OF RESTATED FINANCIAL INFORMATION

Following are the details as per the restated financial statements for the financial years ended on March 31, 2026, March 31, 2025 and March 31, 2024:

(₹ in Lakhs)

Sr. No	Particulars	For the period/ year ended		
		March 31, 2026	March 31, 2025	March 31, 2024
1	Share capital	1,325.49	20.00	20.00
2	Net Worth	4,379.07	1,590.27	1,365.60
3	Revenue	21,416.18	7,794.26	7,573.32
4	EBITDA	2,846.36	499.48	429.63
5	Profit after tax	1,844.78	224.67	266.44
6	Basic Earnings per share	13.95	2.20	2.61
7	Diluted Earnings per share	13.95	2.20	2.61
8	Return on Equity/ Net Worth	61.81%	15.20%	21.62%
9	Net Asset Value per equity share:-			
	NAV per Equity Shares (Based on Actual Number of Shares)	33.04	795.13	682.30
	NAV per Equity Shares (based on Weighted Average Number of Shares - With Bonus issue effect)	33.12	15.59	13.39
10	Total borrowings	2077.21	741.94	684.57
11	Cash flow from operating activities	(662.34)	548.10	80.93
12	Cash flow from investing activities	(1078.16)	(619.20)	(113.15)
13	Cash flow from financing activities	1,865.52	(38.33)	216.49

For further details, please refer to the chapter titled “**Restated Financial Statements**” beginning on page 173 of the Red Herring Prospectus.

SUMMARY OF KEY PERFORMANCE INDICATORS

(₹ In Lakhs except percentages and ratios)

Key Financial Performance	FY 2025-26	FY 2024-25	FY 2023-24
Revenue from operations ⁽¹⁾	21,416.18	7,794.26	7,573.32
EBITDA ⁽²⁾	2,846.36	499.48	429.63
EBITDA Margin (%) ⁽³⁾	13.29%	6.41%	5.67%
PAT ⁽⁴⁾	1,844.78	224.67	266.44
PAT Margin (%) ⁽⁵⁾	8.61%	2.88%	3.52%
RoCE (%) ⁽⁶⁾	40.00%	16.96%	20.00%
RoE (%) ⁽⁷⁾	61.81%	15.20%	21.62%
Net worth ⁽⁸⁾	4,379.07	1,590.27	1,365.60

Notes:

- (1) Revenue from operation means revenue from operating activities.
- (2) EBITDA means Earnings before interest, taxes, depreciation and amortization expense, arrived at by obtaining the profit before tax/ (loss) for the year and adding back interest expenses, depreciation and amortization and impairment expense and reducing other income, and after eliminating non-operating expenses and the effect of extra ordinary and exceptional items.
- (3) ‘EBITDA Margin’ is calculated as EBITDA as a percentage of revenue from operations.
- (4) PAT represents total net profit after tax for the year attributable to owners of the company.
- (5) ‘PAT Margin’ is calculated as PAT attributable to owners of the company divided by Revenue from Operations.
- (6) ROCE is calculated as EBIT divided by capital employed where (i) EBIT means PAT + Tax Expenses + Interest Cost (ii) Capital employed means Net worth + total current & non-current borrowings + DTL-DTA as appearing in financial statements.
- (7) ROE is calculated as PAT attributable to owners of the company as divided by Average Shareholder’s Equity.
- (8) Net Worth = Equity Share Capital + Reserve and Surplus (including surplus in the Statement of Profit & Loss) – Preliminary Expenses to the extent not written-off.

For further details, please refer to the chapter titled “**Basis for Issue Price**” beginning on page 97 of the Red Herring Prospectus.

RISK FACTORS

The below mentioned risks are the top 10 internal risk factors as per the Red Herring Prospectus:

1. We derive a significant portion of our revenue from operations from our top 10 customers with which we do not have any firm commitments. The loss of any one or more of our major customers would have a material adverse effect on our business, cash flows, results of operations and financial condition.
2. Our business is dependent on diagnostic and healthcare companies, and any reduction in their testing volumes, outsourcing requirements, or adverse sector developments could materially and adversely affect our business, financial condition, and results of operations.
3. We are exposed to risks relating to loss, damage, contamination or delay in transportation of diagnostic samples, which could result in client claims, financial liabilities and reputational harm.
4. Our business depends on service-level contracts with clients that are subject to renewal, renegotiation and termination, and our inability to maintain or renew such contracts on favourable terms could materially and adversely affect our business.
5. Our business is working capital intensive and trade receivables constitute a significant portion of our current assets. Any delay or failure in realisation of trade receivables could adversely affect our cash flows, liquidity and financial condition.
6. Our business is highly dependent on the availability and performance of a large, skilled and geographically dispersed workforce, and our inability to effectively manage, train and retain such personnel could adversely affect our operations.
7. Our operations depend on the continuous availability of specialised packaging materials and consumables, and any disruption in their supply or increase in their cost could adversely affect our service delivery and profitability.
8. Misconduct, fraud, negligence or theft by our field personnel could adversely affect our business, reputation and financial condition.
9. Our subsidiary companies has incurred losses and had a negative net worth in the past, and any future losses may adversely affect its financial condition and our consolidated results.
10. We rely on financing from banks or financial institutions to carry on our business operations, and inability to obtain additional financing on terms favorable to us or at all could have an adverse impact on our financial condition. If we are unable to raise additional capital, our business and future financial performance could be adversely affected.

For further details, please refer to the chapter titled “**Risk Factors**” beginning on page 21 of the Red Herring Prospectus.

THE DETAILS OF WEIGHTED AVERAGE COST OF ACQUISITION OF SHARES FOR PROMOTER

PARTICULARS	NUMBER OF EQUITY SHARES HELD AS ON DATE	WEIGHTED AVERAGE COST OF ACQUISITION (“WACA”) PER EQUITY SHARE (IN ₹)	WACA PER EQUITY SHARES ACQUIRED IN LAST ONE YEAR
Promoter(s)			
Ashok Kumar Sharma	36,58,550	-	10.41
Karan Sharma	22,47,825	0.31	-
Tarun Sharma	20,23,550	-	-
Dimple Sharma	1,32,550	-	30.80
Tanveen	35,38,125	-	-

Weighted average cost of acquisition of all shares transacted in the one year and three years preceding the date of draft offer document / offer document.

Period	Weighted Average Cost of Acquisition (in ₹)	Cap Price (₹ [●]) is ‘X’ times the Weighted Average Cost of Acquisition	Range of acquisition price: Lowest Price – Highest Price (in ₹)
Last one year preceding the date of the Red Herring Prospectus	15.23	[●]	0-30.90
Last three years preceding the date of the Red Herring Prospectus	15.60	[●]	0-30.90

BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONNEL		
Sr. No.	Name	Designation (Independent / Whole time / Executive / Nominee)
1.	Tarun Sharma	Chairman & Managing Director
2.	Karan Sharma	Whole Time Director & Chief Financial Officer
3.	Ashok Kumar Sharma	Non-Executive Director
4.	Dimple Sharma	Non-Executive Director
5.	Vanita Yadav	Independent Director
6.	Tejpal Singh	Independent Director
7.	Arpita Abhilasha	Company Secretary & Compliance Officer

For further details, please refer to the chapter titled **“Our Management”** beginning on page 155 of the Red Herring Prospectus.

AUDITOR QUALIFICATIONS

There are no audit qualifications which have not been given effect in the Restated Financial Statements.

SUMMARY TABLE OF OUTSTANDING LITIGATIONS

A summary of outstanding litigations proceedings involving our Company, Promoters, Directors, KMPs, SMPs and Group Company (to the extent material to our Company) as on the date of the Red Herring Prospectus are as below:

(₹ in lakhs)

S. No.	Name of Entity	Criminal Proceedings	Tax Proceedings	Material Civil Litigations	Aggregate amount involved
1.	Company				
	By the Company	-	-	-	-
	Against the Company	-	2	-	62.11
2.	Promoters				
	By the Promoters	-	-	-	-
	Against the Promoters	-	-	-	-
3.	Directors (other than Promoters)				
	By the Directors	-	-	-	-
	Against the Directors	-	-	-	-
4.	Key Managerial Personal & Senior Management				
	By the Company	-	-	-	-
	Against the Company	-	-	-	-
5.	Group Company				
	By the Group Company	-	-	-	-
	Against the Group Company	-	-	-	-

For further details, please refer to the chapter titled **“Outstanding Litigations and Material Developments”** beginning on page 237 of the Red Herring Prospectus.

DECLARATION BY THE COMPANY

We hereby declare that all relevant provisions of the Companies Act, 1956, the Companies Act, 2013 and the guidelines/regulations issued by the Government of India or the guidelines/regulations issued by the Securities and Exchange Board of India, established under Section 3 of the Securities and Exchange Board of India Act, 1992, as the case may be have been complied with and no statement made in the Herring Prospectus is contrary to the provisions of the Companies Act, 1956, the Companies Act, 2013, the Securities and Exchange Board of India Act, 1992 or rules made or guidelines or regulation issued there under, as the case may be. We further certify that all statements in the Red Herring Prospectus are true and correct.